By MEGGLE Excipients
Double presence for MEGGLE at API China in Shanghai
Wasserburg, Germany: – Pharmaceutical excipient industry leader MEGGLE will be highly visible at the major upcoming expo API China, now firmly established as a central event in the Chinese pharma calendar.
MEGGLE will be represented on two stands at the Shanghai National Exhibition and Convention Centre via its regional partners: Standard Pharma at Booth 1.2 M33 and Pintect Pharma at Booth 1.2L45. MEGGLE professionals from its Shanghai bureau will be present on both stands to answer technical questions.
Key event
This is a return to API China for MEGGLE, recognizing that over the course of only eight years the event has become one of the country’s leading pharmaceutical shows. The 2024 show is expected to attract more than 1,000 exhibitors and at least 60,000 visitors.
API China is based on a huge B2B platform for trading, knowledge sharing, exchange and cooperation and with application fields that include ingredient and excipient sourcing, pharma and biotech R & D, engineering design, manufacturing, and packaging.
About MEGGLE Wasserburg
Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.
MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.
The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.
To learn more, visit: https://www.meggle-pharma.com/en/home.html
About API China
Founded in 2016, the API China expo has expanded to become one of Asia’s premier pharmaceutical trade shows. The main show covers some 50,000 active ingredients organized in 24 categories, reflecting China’s prominence as a major world supplier.
API China is a three-day event opening May 15 at the Shanghai National Exhibition & Convention Center. The event incorporates three co-located exhibitions: PharmEx for ingredients and excipients, PharmPack for packaging machinery and Sinophex for pharmaceutical equipment. New for 2024, API China will also be collocated with PHARMCHINA and China International Natural Health & Nutrition Expo (NHNE), creating a comprehensive platform that interacts with the pharmaceutical and health nutrition industry chain.
The event is organized by API China with further information at: https://www.apichina.com.cn/#/conferenceIntro
Resources
Click on MEGGLE Product Configurator for further information.
Click on MEGGLE Company Overview to learn more.